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INTRODUCTION
The cancer stem cell theory states that tumors contain a subset of
cells that are capable of self-renewal and differentiation, can
propagate tumor growth, and are resistant to apoptosis [1]. Recent
evidence shows that cancer tissue contains a hierarchical organ-
ization of cells including stem cells similar to normal tissue. These
stem-like cancer cells are similar to normal stem cells [2,3] and can
be responsible for cancer progression and metastasis. Normal stem
cells can be transformed into cancer stem cells after genetic
modifications such as mutations in oncogenes, tumor suppressor
genes, and repair genes or due to epigenetic alterations such as
histone modification and abnormal methylation [4]. Recently,
several cancers including those of the blood [5,6], breast [7], brain
[8], and colon [9] were shown to have stem-like cells. Presence of
these stem-like cells in solid tumors was first reported in human
breast tumor samples [7].
Subsequently, several other human solid tumors have been
studied for the presence of tumor initiating stem-like cells.
CD133 has been shown to be a marker of cancer stem cells. It is a
five transmembrane domain glycoprotein expressed by untrans-
formed hematopoietic and neural progenitors [8,10]. It has been
reported that cancer cells expressing stem cell markers are
chemoresistant and could thus be responsible for clinical relapse
[11]. Mahller et al. [12] have reported the presence of pluripotent
tumor initiating cells in neuroblastoma cell lines that are CD133 and
nestin positive and are susceptible to a targeted oncolytic virus.
Glioblastoma-derived CD133þ and CD133 cells have been
shown to have differential growth characteristics and molecular
profiles [13]. Singh et al. [8] have shown that human brain
tumors contain CD133þ stem-like cells that are capable of growing
tumors in immunodeficient mice. Nineteen to 29% of cells in
glioblastomas and 6–21% of cells of medulloblastomas are reported
to be CD133þ and tumorigenic [3].
Neuroblastoma is the most common extra-cranial solid tumor of
childhood. It causes, approximately, 15% of deaths attributable to
malignant conditions in children [14]. Despite multimodal treat-
ment, the outcome of high-risk neuroblastoma is still dismal with a
EFS <50% [12]. One of the major causes of poor outcome is drug
resistance which leads to treatment failure. Based on the above
reports, we hypothesize that CD133þ cells isolated from neuro-
blastoma cancer cell lines are more resistant to commonly used
chemotherapeutic agents namely cisplatin, etopside, doxorubicin,
and carboplatin than CD133 cells. In this study, CD133-
expressing stem-like cells were positively isolated from the
neuroblastoma cell lines SK-N-SH and SK-N-BE, and the effect
of commonly used chemotherapeutic agents was studied on
CD133þ and CD133 populations. Here we report that CD133þ




Human neuroblastoma cell lines SK-N-BE and SK-N-SH were
obtained from American Type Culture Collection, Rockville, MD
and SH-SY-5Y, osteosarcoma cell lines U2OS and P16T, and Ewing
sarcoma cell line EWS-1 were obtained from the Children’s
Hospital of Michigan Cell Culture Laboratory frozen-stored cell
bank. After thawing, the cells were cultured in RPMI medium
(RPMI; Fisher Scientific, Pittsburg, PA) supplemented with 10%
FBS (Invitrogen, Carlsbad, CA) and 1% antibiotic/antimycotic
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CD133þ cells compared to CD133 cells by PI/Annexin V-binding
assay. Western blot analysis showed that CD133þ cells expressed
less MKP-1. Phosphorylated forms of both ERK and P-38 kinases
were expressed at higher levels in CD133þ cells than in CD133
cells. Conclusions. This study suggests that CD133þ cells are more
resistant to anticancer drugs than CD133 cells. Differences in the
expression and phosphorylation of kinases could be partially
responsible for this difference. Targeting CD133-expressing cells
could be a strategy to develop more effective treatments for
neuroblastoma. Pediatr Blood Cancer 2010;54:361–368.
 2009 Wiley-Liss, Inc.
Key words: cancer stem cells; drug resistance; neuroblastoma
 2009 Wiley-Liss, Inc.
DOI 10.1002/pbc.22351
Published online 19 November 2009 in Wiley InterScience
(www.interscience.wiley.com)
——————
Additional supporting information may be found in the online version
of this article.
The Carman and Ann Adams Department of Pediatrics, Children’s
Research Center of Michigan, Wayne State University School of
Medicine, Children’s Hospital of Michigan, Detroit, Michigan
Conflict of interest: Nothing to report.
*Correspondence to: Sharada D. Vangipuram, Children’s Hospital of
Michigan, 3901 Beaubien Street, 3N73, Detroit, MI 48201.
E-mail: svangipuram@med.wayne.edu
Received 16 July 2009; Accepted 1 October 2009
solution, in a humidified atmosphere containing 5% CO2 at 378C.
Cells were trypsinized and passaged at a ratio of 1:3 at confluence or
washed in culture medium and counted for experiments.
Immunophenotyping by FACS Analysis
Trypsinized cells were washed in ice-cold PBS and stained for
CD133 expression as previously explained by Barami et al. [15].
Briefly, the cells were resuspended in PBSþ 30% adult bovine
serum at a concentration of 5 106 cells/ml and added to twelve
75 mm tubes at 100 ml/tube containing pre-aliquoted monoclonal
antibodies CD133 PE and CD45 FITC. After incubating cells with
antibody in the dark for 30 min at room temperature, the cells were
washed with 1 ml of cold PBS and resuspended in 0.5 ml of
PBSþ Fix (PBSþ 2.5% Coulter Fixative). A two-color analysis
was performed using a Coulter XL Flow Cytometer (Coulter Corp.,
Miami, FL) gated on the viable cell population as inferred from
forward and side scatter (FS and SS) analyses. Cells were incubated
with isotype-matched controls for all samples.
Isolation of CD133þ Cell Population
Confluent layers of SK-N-SH or SK-N-BE cells were trypsi-
nized and washed with PBS. CD133þ cells were positively
selected from the cell suspension using MACS cell isolation kit
(Miltenyi Biotechnologies, Auburn, CA). Briefly, the cells were
resuspended in PBS containing 0.5% bovine serum albumin and
2 mmol/L EDTA and incubated with CD133/1 antibody labeled
magnetic microbeads for 30 min at 48C. Subsequently, CD133þ
cells were isolated by magnetic cell separating columns. The
purity of the isolated cell population was estimated by flow
cytometry using anti-CD133 or isotype control antibody (Milte-
nyi Biotechnologies).
Equal numbers of EWS-1 cells with high percentage of CD133þ
cells were incubated either with anti-CD133 antibody-labeled
magnetic microbeads or with media for 30 min at 48C to serve as
positive control. Subsequently, the cells were washed and treated
with various doses of chemotherapeutic agents and percentage live
cells estimated by MTT assay as described below.
Treatment With Chemotherapeutic Agents
CD133þ and CD133 cells from cell lines were seeded in 96-
well tissue culture plates at a density of 10 103 cells/well and
incubated for 24 hr before the addition of various drugs. The cells
were incubated with various doses of Cisplatin (0–50 mg/ml;
SICOR Pharmaceuticals, Irvine, CA), etopside (0–200 mg/ml),
and doxorubicin (0–200 ng/ml; Bedford Laboratories, Bedford,
OH), and carboplatin (0–200 mM; SICOR Pharmaceuticals, CA),
for 24, 48, or 72 hr. At the end of the incubation period the cell
survival was directly estimated by MTT assay or the cells were
trypsinized and used for Annexin V/PI analysis or lysed for
Western blot analysis.
MTT Assays
MTT assays were performed as previously described [16].
Briefly, at the end of the incubation period with cisplatin, etopside,
carboplatin, or doxorubicin, the cells were incubated with MTT
solution, and subsequently acid isopropanol was added to dissolve
formazan crystals. Absorbance was measured using a Vmax
microplate reader (Molecular Devices, Sunnyvale, CA) at 590 nm,
and percentage of cell survival was calculated.
Detection of Apoptosis Using Annexin V/PI Staining
The protocol described by Ozgen et al. [17] was modified and
used for the detection of apoptosis. Cells from control (with no drug
added) and experimental 96-well plates were trypsinized and
resuspended at a concentration of 1 or 2 106 cells/ml in RPMIþ
10% FBS. Apoptosis was estimated using the Apoptosis Detection
Kit (R&D Systems, Minneapolis, MN). Briefly, 50 ml of cell
suspensions was stained by adding 10ml of diluted Annexin V–
FITC (AnxV) and 10 ml of 250 mg/ml of propidium iodide (PI). After
15 min of incubation in the dark, the reaction was diluted with 0.4 ml
of binding buffer and then analyzed using a Coulter XL Flow
Cytometer (Coulter Corp.). Cells were gated to include the viable
cell populations based on FS and SS character, and these gated
events were analyzed on two-color histograms to identify Annexin-
V-expressing cells. Drug sensitivity and treatment variables were
assessed by the addition of Flow Count Fluorospheres (Coulter
Corp.) to the final 0.4 ml of added binding buffer. The reactions were
performed with drug-treated and control cells that had been initially
cultured at identical cell densities and then harvested and
resuspended in equivalent volumes. Absolute, relative viable, dead,
and apoptotic counts were determined by tracking the Flow Count
beads in the FL2 channel.
Polyacrylamide Gel Electrophoresis (PAGE)
and Western Blotting
Whole-cell lysates were prepared as described [16]. Cell lysates
(30–100 mg) were electrophoresed through 4–10% SDS–PAGE.
The separated proteins on gels were transferred to PVD membranes
(Schleicher & Schuell, Inc., Keene, NH) using Bio-Rad mini gel
electrotransfer system. Non-specific binding was blocked with
blocking buffer containing 10% fat-free milk powder in phosphate-
buffered saline (PBS) for 1 hr at room temperature, followed by
incubation with primary antibodies in blocking buffer with 5% fat-
free milk powder overnight at 48C and room temperature for 1 hr.
The membrane was then washed three times with PBS, and
incubated with secondary antibody for 1 hr at room temperature and
washed three times. The bound antibody was detected using
Chemiluminescence reagent (Amersham Pharmacia Biotech,
Piscataway, NJ) according to the manufacturer’s protocol.
Statistical Analysis
Data are expressed as mean SD. The mean percentages of live
or dead cells between groups were compared using parametric
independent samples t-test. Appropriate assumptions (normality
and/or homogeneity of variances) were checked and verified.
Statistically significant differences were considered achieved with a
P-value <0.05.
RESULTS
Approximately, 85% of cells in the Ewings sarcoma cell line
EWS-1 were CD133þ (Fig. 1A) while neuroblastoma cell lines SK-
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N-SH and SK-N-BE contained 8–10% and 3–5% CD133þ cells,
respectively (Fig. 1B,C). Neuroblastoma cell line SH-SY-5Y and
osteosarcoma lines U20S and P16T had less than 0.5% CD133þ
cells (Fig. 1D–F).
CD133-expressing cells were positively isolated from cell line
SK-N-SH using magnetic microbeads and the purity of the
population was subsequently confirmed by immunophenotyping.
Greater than 85% of the isolated cells expressed CD133.
CD133þ and CD133 cells from the cell line SK-N-SH treated
with various concentrations of chemotherapeutic drugs resulted in a
dose-related reduction in the percentage of live cells as estimated by
MTT assay at 24, 48, and 72 hr (Fig. 2A–D). Further in all cases,
CD133þ population had a significantly higher percentage of live
cells compared to CD133 population. At 24 hr of treatment,
although there was a higher percentage of live cells in CD133þ
population, statistically significant difference was not observed
between the CD133þ and CD133 groups with cisplatin, etopside,
doxorubicin, and carboplatin treatment as estimated by the MTT
assay. However, after 48 hr of treatment with cisplatin at concen-
trations 6.25–50 mg/ml, CD133þ population had a significantly
higher percentage of live cells than CD133 population. Similarly,
at etopside concentrations of 12.5–200 mg/ml and doxorubicin at
100–200 mg/ml CD133þ cells had significantly greater percentages
of live cells. At 72 hr, at all doses tested of cisplatin (3.125–50mg/
ml) etopside (3.125–200 mg/ml), doxorubicin (3.125–200 ng/ml),
and carboplatin (12.5–200 mM/ml), a significantly higher percent-
age of live cells were estimated in CD133þ populations (Fig. 2).
Estimation of the percentage dead or apoptotic cells in both
groups treated with low and high doses of drugs using Annexin V/PI
detection kit showed that CD133þ had a significantly lower
percentage of dead cells relative to control compared to the CD133
group consistent with the result obtained by the MTT assay (Fig. 3).
These results suggest that CD133þ cells are more resistant to drug-
induced apoptosis compared to CD133 cells.
CD133þ and CD133 cells from the cell line SK-N-BE treated
with various concentrations of cisplatin resulted in a dose-related
reduction in the percentage of live cells as estimated by MTT assay
at 24 hr. Further in all cases, CD133þ population had a significantly
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 1. Percentage of CD133 expressing cells in cell lines: (A) EWS-1: 85%; (B) SK-N-SH: 8–10%; (C) SK-N-BE: 3–5%; (D) SH-SY-5Y:
<0.5%; (E) U20S: 0.5%; and (F) P16T: <0.5%.
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higher percentage of live cells compared to CD133 population
(Fig. 4).
EWS-1 cell line with>85% CD133þ cells was used as a control
to estimate the possible role of the microbeads used to isolate
the CD133þ cells in the observed resistance. The presence of
microbeads caused no difference in cell viability compared to cells
without beads at all doses tested with cisplatin, etopside,
doxorubicin, and carboplatin (data shown as Supplemental
Information Online, Fig. 6).
Western blot analysis was performed to study the levels of
phosphorylated and total forms of select MAP kinases involved in
apoptotic and cell survival mechanisms (Fig. 5). CD133þ cells
constitutively expressed lower levels of MKP-1 compared to
CD133 population. Phosphorylated P-38 and P-ERK were
expressed at significantly higher levels in CD133þ cells while
there was no difference in the expression of phosphorylated form of
P-JNK and the expression of total P-38, ERK, or JNK kinases
between CD133þ and negative groups.
DISCUSSION
According to the cancer stem cell theory, cancers develop from a
small number of stem-like cells that are capable of self-renewal as
well as differentiation. These cells are resistant to conventional drug
therapies and have a high drug efflux capacity [11,18,19]. Cancer
stem cells have been identified in acute myeloid leukemia [5]
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 2. Percentage of live cells in CD133þ and CD133 populations of cell line SK-N-SH after exposure to chemotherapeutic agents.
A: Cisplatin—48 hr; (B) cisplatin—72 hr; (C) etopside—48 hr; (D) etopside—72 hr; (E) doxorubicin—48 hr; (F) doxorubicin—72 hr;
(G) carboplatin—72 hr. Values are expressed as a percentage of untreated controls and are mean SD (n¼ 6; *P< 0.05). [Color figure can be
viewed in the online issue, which is available at www.interscience.wiley.com.]
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expressing stem cell markers CD34þ and CD38. They could
generate original tumors with different phenotypes. Side population
(sp) cells that export Hoechst 33342 dye have been used to identify
stem-like cells in certain cancers, that generated sp and non-sp cells
ex vivo [11,18].
CD133 is a stem cell marker expressed by normal neuronal stem
cells [20]. Singh et al. [8] have shown that CD133þ cells isolated
from human brain tumors could develop tumors in mice while
CD133 cells were not tumorigenic. Identifying stem-like cancer
cells from existing cancer cell lines could lead to development of
effective targeted therapies. Here we utilized the marker CD133 to
identify the presence or absence of stem-like cells in various cell
lines derived from human solid tumors. The tumorigenicity and
differentiation potential of these CD133þ cells are yet to be
determined. However, identifying differential responses of
CD133þ and CD133 cells to chemotherapeutic agents could give
a better insight into the effect of anticancer medications on cancer
cell lines. Ewing sarcoma cell line EWS-1 contains a very high
percentage (>85%) CD133þ cells while neuroblastoma cell
line SK-N-SH has 8–10% CD133þ cells. We suggest that SK-N-
SH cell line can serve as a model to study the differences in the
cytotoxic effects of various anticancer drugs between CD133þ and
CD133 cells.
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 3. Percentage of dead and apoptotic CD133þ/ cells after treatment with chemotherapeutic drugs as determined by the Annexin V/PI-
binding assay. Values are expressed as a percentage of dead and apoptotic cells in untreated controls and are mean SD (n¼ 6; *P< 0.005). [Color
figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
Fig. 4. Percentage of live cells in CD133þ and CD133 populations
of cell line SK-N-BE after exposure to cisplatin for 24 hr as determined
by the MTT assay. Values are expressed as a percentage of untreated
controls and are the mean SD (n¼ 5; *P< 0.05). [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
Fig. 5. Expression of kinases in CD133þ and CD133 populations of
neuroblastoma cell line SH. A: MKP-1, (B) phospho-P-38, (C) P-38, (D)
phospho-JNK, (E) total JNK, (F) phospho-ERK, (G) total ERK, and (H)
b-actin. The results are representative of two separate experiments.
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Several mechanisms have been proposed to explain the
resistance of cancers to chemotherapeutic agents, including altered
gene expression [21], hypoxia in the tumors [22], and migration of
tumor cells to low drug penetration sites [23]. Keshelava et al. [24]
have reported that the resistance of neuroblastoma cell lines is
dependent on the patient’s phase/stage of therapy when the cell lines
were derived. However, in recent years, cancer stem cells have been
an important focus in the study of drug resistance mechanisms [25–
29]. We investigated the sensitivity of CD133þ and CD133 cells
from the cell line SK-N-SH to four drugs commonly used for
neuroblastoma treatment: cisplatin, etopside, doxorubicin, and
carboplatin.
Keshelava et al. [24] have also shown that for cell lines derived
from children with neuroblastoma both doxorubicin and carboplatin
had a very high range of sensitivity compared to cisplatin
and etopside. For this study we chose a wide range of drug
concentrations to cover both low-dose and high-dose treatments and
the concentrations correspond to the dosages used to treat patients
[30–34]. MTT assay has been used as a predictor of drug sensitivity
in vitro for several types of tumors [35–37]. Here we determined
that CD133þ cells isolated from cell line SK-N-SH are more
resistant to cisplatin, etopside, carboplatin, and doxorubicin at 72 hr.
CD133þ cells had significantly higher percentages of live cells at all
doses of the drugs tested.
Although anti-CD133-labeled magnetic microbeads have been
extensively used for CD133þ cell isolation [38–43], we eliminated
the possibility of the beads interfering in the observed differences
by studying the effect of the chemotherapeutic drugs on
CD133þ rich EWS-1 cell line, in the presence and absence of the
beads. The presence of microbeads conferred no apparent change to
the chemosensitivity of the cells (data available as a Supplement
Online).
CD133þ cancer stem cells from glioblastomas cell lines show
significant resistance to chemotherapeutic agents temozolomide,
carboplatin, paclitaxel, and etopside compared to CD133-negative
cells [44] similar to our observation with SK-N-SH and SK-N-BE
derived CD133þ cells. Mahller et al. [12] have reported the
presence of pluripotent tumor initiating cells in neuroblastoma cell
lines that are CD133 and nestin positive, had increased ABCG2
expression, and were resistant to doxorubicin. Shervington and Lu
[45] have shown that CD133-expressing glioblastoma cells co-
express multidrug resistance genes such as mdr1 and bcl-2, and Liu
et al. [44] have associated high drug resistance of CD133þ cells to
expression of BCRP1 and MGMT. An in-depth gene profiling of
CD133þ and CD133 fractions of SK-N-SH cell line could
identify the differences in gene expressions and help develop gene
targeted therapies.
Mitogen-activated protein kinases (MAP kinases) play impor-
tant roles in cell-cycle progression, differentiation, cell survival, and
apoptosis. Three major groups comprise the family of MAP kinases:
the extracellular regulated kinases (ERKs), the C-jun N terminal
kinases (JNKs), and the p38MAP kinases [46,47]. An initial
screening of the constitutive expression of kinases and phosphatase
MKP-1 by Western blot analysis showed that CD133þ cells
expressed higher levels of the phosphorylated forms of P-ERK and
P-P38 while the expression of kinase-phosphatase MKP-1 is higher
in the CD133 cells.
Four mechanisms have been proposed for the resistance of
solid tumors to platinum-based drugs: (1) reduced platinum
accumulation, (2) intracellular inactivation of cisplatin, (3)
enhanced repair of DNA damage, and (4) blocking the induction
of apoptosis and promoting cell survival [48]. Differential
expression of MAP kinases (P-38, JKN, ERK, and P13K) has
been implicated in the cell survival mechanism [48]. Although
the traditional role of activated P-38 is in cell differentiation,
growth inhibition, and apoptosis [49], Thornton and Rincon [47]
have reported that P-38 also contributes to cell survival by induction
of G2/M cell-cycle checkpoint in tumor and non-tumor cells.
Kinases ERK1/2 have been implicated in the tumor cell survival
signaling as reviewed by Balmanno and Cook [50]. Although total
ERK1 (p44) is prominently expressed in both CD133þ and
CD133 populations, conspicuously low levels of ERK2 (p42)
are seen in both groups. However, the phosphorylated forms of
both ERK 1 and ERK2 are expressed in significantly higher levels
in CD133þ cells possibly playing a role in the increased survival
of CD133þ cells. JNKs are activated by various external stimuli
such as environmental stresses, cytokine response, oxidant stress,
and DNA damage [51]. Interestingly, we find no significant
difference in the activated form of JNK between CD133þ and
CD133 cells. While the kinase cascade plays an important role in
the activation of downstream kinases by phosphorylation, regulated
dephosphorylation of MAPKs is crucial to determine the magnitude
and duration of activation, thus determining the physiological
outcome [52]. Mitogen-activated protein kinase phosphatase 1
(MKP-1) has been shown to dephosphorylate ERK, JNK, and P-38
in the cell nucleus [52]. Higher expression of MKP-1 in CD133
cells relates to the increased dephosphorylation of P-38 and ERK
seen in CD133 cells. Differential activations of various MAPKs
determines the cell fate by triggering downstream regulators
toward apoptotic, cell survival, or differentiation pathways.
Here we show that the CD133þ stem cell fraction of the SK-N-
SH line has constitutively higher levels of phosphorylated P-38
and ERK1/2. This could be one of the pathways by which
cancer stem cells show higher resistance to chemotherapeutic
drugs. A detailed study of the MAPK expression in CD133þ/ cells
after treatment with anticancer agents would allow us to determine
the role of kinases in chemoresistance and could lead to more
effective therapies.
In summary, this study shows that CD133þ cells in neuro-
blastoma cell lines SK-N-SH and SK-N-BE are more resistant to
conventional anticancer drugs compared to CD133 cells. Differ-
ences in the activation of MAPKs and expression of MKP-1 could
be partially responsible for the resistance. Further investigation is
warranted to confirm the role of kinases since they may serve as
molecules for targeted therapy. Similar studies are needed to be done
on primary neuroblastoma tissue samples from patients to ensure
the presence, and drug resistance of CD133þ cells. Targeting
these CD133þ cell populations using novel agents or novel
combinations of existing drugs could be one of the strategies to
overcome resistance and develop more effective treatment for
neuroblastoma.
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